Deletions in SARS-CoV-2 Spike protein drive antibody escape, study shows
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
List view / Grid view
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
Researchers found that SARS-CoV-2 persists in the brain after it is cleared in the lungs and concluded the severest and longest lasting symptoms of COVID-19 may be caused by brain infection.
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.